Trial | RT | Placebo | N | Median F/U (yr) | Local Recurrence Rate (%) | Contralateral Breast Cancer Rate (%) | Breast Cancer Mortality (%) | Overall Death (%) |
NSABP B-24 [31] | RT | Placebo | 900 | 13.6 | 16.6 | 8.1 | 2.7 | 14.4 |
|
| Tamoxifen | 899 | 13.6 | 13.2 | 4.9 | 2.3 | 12.2 |
UK/ANZ DCIS [26] | No RT | Placebo | 544 | 12.7 | 11.6 | 2.8 | 2.0 | 10 |
|
| Tamoxifen | 567 | 12.7 | 8.7 | 1.4 | 3.0 | 10 |
| RT | Placebo | 267 | 12.7 | 4.0 | 1.7 | 1.0 | 10 |
|
| Tamoxifen | 316 | 12.7 | 3.4 | 1.5 | 2.0 | 14 |